Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants. - Wikidata - awgldk - TriplyDB

Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.

Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.

http://www.wikidata.org/entity/Q36892604

about

Linking Pesticide Exposure with Pediatric Leukemia: Potential Underlying Mechanisms Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation.Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis.MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.The evolution of clinical trials for infant acute lymphoblastic leukemia.Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research.The development of targeted new agents to improve the outcome for children with leukemia.MLL-ENL-mediated leukemia initiation at the interface of lymphoid commitment.Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes.Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis.MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance Clinical and molecular epidemiology of neonatal leukemia in Brazil.Ligand-independent FLT3 activation does not cooperate with MLL-AF4 to immortalize/transform cord blood CD34+ cells.The role of constitutive activation of FMS-related tyrosine kinase-3 and NRas/KRas mutational status in infants with KMT2A-rearranged acute lymphoblastic leukemia.RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia.MLL1 Promotes IL-7 Responsiveness and Survival during B Cell Differentiation.Trametinib inhibits RAS-mutant MLL-rearranged acute lymphoblastic leukemia at specific niche sites and reduces ERK phosphorylation in vivo.Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol.New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update.De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia.Relapsed infant MLL-rearranged acute lymphoblastic leukemia with additional genetic alterations.Impact of mutations in FLT3, PTPN11 and RAS genes on the overall survival of pediatric B cell precursor acute lymphoblastic leukemia in Brazil.Subclonality and prenatal origin ofRASmutations inKMT2A (MLL)-rearranged infant acute lymphoblastic leukaemia

P2860

Q26752627-02D14998-4076-4DE7-B2B2-B79BB7387678 Q26783577-CC620337-82B3-49D8-B723-0E73067C7DAA Q28555124-F3E74EC4-5B22-42FC-AF8D-DEF2D05A9169 Q34465221-80B31EFC-3E32-4BF9-816B-473B3EFA4A82 Q34580110-049F6D2C-FBF0-40E4-AEA5-8D53D0BBC560 Q35018755-BE08E34D-3D82-4C52-8226-42A478618034 Q36771918-0AD4A2E5-8A7A-49A8-B04B-468413660043 Q37306997-0C933510-528A-4F63-B7AB-4F18F6E89F1F Q37633585-2C51D17D-0780-4B82-8823-82A4A68E41E9 Q37730023-079C39E7-F7DA-4E37-A540-CD248D73C29B Q38227885-B421807E-1868-4EF2-9C7A-293E33606520 Q38679992-CDF72D41-6F12-4D2E-9F8B-515678033612 Q38964974-1C5D2532-CE7D-4BF5-9B96-070C386CD515 Q39031605-E147C8BB-B3BA-4E72-90D2-BFCE9F7FA1B7 Q39992854-5242BF31-8EFA-4780-8071-6EA0E3DA6037 Q42261202-E79FEC8A-896A-4669-8FEF-A67F576C7351 Q42314704-23F72FCE-8002-4576-9C37-2636EBAB3AC1 Q42660698-72E6DA45-97BF-4CE3-9A88-E16BE0EF26B7 Q44833746-64CA9A46-A3DB-4E0A-BF36-D6EA849F9D80 Q45399384-0BC5B327-C843-4567-A877-BF925906C199 Q47142470-587F484C-329F-4CF9-9760-7E6396003A12 Q47875530-63A2CCD2-6FA8-46F8-9FE0-052AB75D7D1A Q47884832-B7FD94FF-9949-4E54-811A-99F7B7CFAEA4 Q48204980-56B8080C-DC97-47A9-B452-9638EAD348C0 Q50118866-887D3B2B-6F9E-419B-83AA-C763BC5C4EB8 Q50854409-806F42CE-B07F-402E-AE2F-C18B28B8448B Q52593673-FC62CA0F-8548-4A10-9144-211350ED71A3 Q52714487-274A9DB5-CE32-4196-B5CF-D0F2AB99BB52 Q54240944-57C0A1EB-AC27-4894-924F-1D48F5D087C5 Q54406965-FAC6A469-C32B-4D3D-ACDB-0F3FD680151C Q58492859-BC8F925F-D3F3-41D8-B1AD-BD77142292B1

P2860

Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.

http://www.wikidata.org/entity/Q36892604

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Frequencies and prognostic imp ...... hoblastic leukemia in infants.

@en

type

label

Frequencies and prognostic imp ...... hoblastic leukemia in infants.

@en

prefLabel

Frequencies and prognostic imp ...... hoblastic leukemia in infants.

@en

P1433

Q36892604-CE958A9C-282A-4B87-AF17-B833D2AE2170

P1476

Q36892604-472A334B-9AD4-414C-B1F9-79FFFE72C786

P2093

Q36892604-5D36B469-1D7A-4179-95ED-B6021441A7C1

Q36892604-64046828-187E-4A23-ACF1-4A9196D1ACE6

Q36892604-7BB026BB-7BBF-41B3-9DB1-8F4B8CEFAFE1

Q36892604-8BBC9D37-2175-438A-A041-B36EDAE84309

Q36892604-9EB7DAC2-F6B4-455B-9E21-56B313E67891

Q36892604-EE21EEE9-1B14-4332-9F5D-1348D45A6159

Q36892604-F8AA8481-1DAD-4047-8C79-C476956E83D7

P2860

Q36892604-02CAD4B7-14CC-4D16-BC49-EFE578B6903B

Q36892604-09FFD27D-C43C-421C-A0A9-8CE89B3548A2

Q36892604-0C7913DB-CD0F-4C0C-8168-7CDCF948235E

Q36892604-0E35C59B-A3C2-4C93-BD1E-0A8F260C063C

Q36892604-1586D9B4-1D25-462E-A927-BAC4E3072A72

Q36892604-2074B74A-1A99-4472-A145-9C0058CE3FC4

Q36892604-275835F1-26CA-4BD5-8C96-87A2F0B74446

Q36892604-27D344F4-DF96-445B-8816-6DE9365B88D1

Q36892604-390EEEDD-8AF0-4359-9679-3D14B75D34D1

Q36892604-4A423F06-7B41-4499-AA3D-16C1282B12B9

P304

Q36892604-7869642E-D480-4029-95B5-50753CBB747B

P31

Q36892604-2893BD3F-E294-44FB-985F-EEA0E472A6F6

P356

Q36892604-2BC5711B-BC96-4B1D-8020-E15F150294A5

P433

Q36892604-974ACEF8-052A-46CA-8124-51C7002AD361

P478

Q36892604-5AB994F7-F6A1-47E0-A278-40B6F15F9CA9

P50

Q36892604-8FA63518-8FCD-476F-A37E-56F6CD4E7163

P577

Q36892604-ED4E40AD-67C1-4EBA-A7AD-012C61F22BC8

P5875

Q36892604-FB9D4327-9D0C-4D7F-9F56-CA7AD1A71668

P698

Q36892604-C867B752-3C71-488F-A186-008845BF8EEA

P921

Q36892604-A375A43A-4C7C-4077-B673-4FF5E3E9AE24

P932

Q36892604-97C8E919-8706-4F31-A2EA-A84A976A43FC

P356

HAEMATOL.2012.067983

P1433

P1476

Frequencies and prognostic imp ...... hoblastic leukemia in infants.

@en

P2093

Eddy H J van Roon

http://www.w3.org/2001/XMLSchema#string

Emma M C Driessen

http://www.w3.org/2001/XMLSchema#string

Jill A P Spijkers-Hagelstein

http://www.w3.org/2001/XMLSchema#string

Maria Grazia Valsecchi

http://www.w3.org/2001/XMLSchema#string

Paola de Lorenzo

http://www.w3.org/2001/XMLSchema#string

Pauline Schneider

http://www.w3.org/2001/XMLSchema#string

Ronald W Stam

http://www.w3.org/2001/XMLSchema#string

P2860

Gene Expression Omnibus: NCBI gene expression and hybridization array data repository

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias

H3K79 methylation profiles define murine and human MLL-AF4 leukemias.

HOXA9 is required for survival in human MLL-rearranged acute leukemias.

Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.

In utero origins of childhood leukaemia.

Activation of Ras-dependent Elk-1 activity by MLL-AF4 family fusion oncoproteins.

P304

937-944

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2012.067983

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235603590

http://www.w3.org/2001/XMLSchema#string

P698

23403319

http://www.w3.org/2001/XMLSchema#string

P921

P932

3669451

http://www.w3.org/2001/XMLSchema#string